Article

Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degraders

2025-03-28

Abstract excerpt

Precise control of pre-mRNA splicing is critical for transcriptome integrity, and its disruption is increasingly recognised as a vulnerability in cancer. Here, we identify a functional interplay between two key splicing regulators, RBM39 and serine/arginine protein kinase 1 (SRPK1), and show that dual targeting of these factors severely compromises splicing fidelity in high-risk neuroblastoma. We use the molecular...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1c972a5b-4fe8-5abd-8e70-cbb581e59a32
DOI: 10.1101/2025.03.28.644532

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degradersDOI 10.1101/2025.03.28.644532Read

Targeting the spliceosome through RBM39 degradation results in exceptional responses in high-risk neuroblastoma modelsSemantic proximity Read

Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinomaSemantic proximity Read

A molecular glue RBM39-degrader induces synthetic lethality in cancer cells with homologous recombination repair deficiencySemantic proximity Read

Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma.Semantic proximity Read

Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15.Semantic proximity Read

RBM39 degrader invigorates natural killer cells to eradicate neuroblastoma despite cancer cell plasticitySemantic proximity Read

Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastomaSemantic proximity Read

Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer.Semantic proximity Read

Combining selinexor with alisertib to target the p53 pathway in neuroblastomaSemantic proximity Read

YAP/TAZ interacts with RBM39 to confer resistance against indisulamSemantic proximity Read

Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.Semantic proximity Read

Targeting replication stress in neuroblastoma by exploiting the synergistic potential of second generation RRM2 and CHK1 inhibitorsSemantic proximity Read